Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group

Polycystic Ovary Syndrome Clinical Trial

Official title:

Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01350895
• Other study ID #: WFH-PCOS-100002
• Status: Completed
• Phase: N/A
• First received: May 9, 2011
• Last updated: November 4, 2013
• Start date: February 2011
• Est. completion date: April 2012

Study information

• Verified date: November 2013
• Source: Taipei Medical University WanFang Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To study the clinical and biochemical characteristics women with polycystic ovary syndrome (PCOS) in different aged groups.

Description:

Polycystic ovarian syndrome (PCOS) is the most frequent endocrine disorder of reproductive age women, affecting an estimated 9-18% of all women in this age group. To diagnose of PCOS in early life is especially important because it is now thought to increase metabolic and cardiovascular risks. Investigating PCOS is crucial as it is now considered to increase metabolic and cardiovascular risk, thereby impacting the health of women to a much greater extent than previously thought. We are plan using retrospective analysis to evaluate the clinical and biochemical presentation of PCOS in different aged groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 781
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 46 Years

Eligibility

Inclusion Criteria:

• Reproductive age women with sufficient data

Exclusion Criteria:

• Disorders of uterus (e.g. Asherman's Syndrome, Mullerian agenesis) and chromosomal anomalies (e.g. Turner syndrome)

• women who had had menarche at less than 3 years of age, Day 3 FSH > 15, or who were older than 46

• women with inadequate clinical/biochemical records

• and women who had had ovarian cysts or ovarian tumors in ultrasonography examination

• pregnancy women

Related Conditions & MeSH terms

• Polycystic Ovary Syndrome
• Syndrome

Locations

Country	Name	City	State
Taiwan	Taipei Medical University-WanFang Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Taipei Medical University WanFang Hospital

Country where clinical trial is conducted

Taiwan,